MX2014013858A - Metodo para tratar un cancer positivo de gd2. - Google Patents

Metodo para tratar un cancer positivo de gd2.

Info

Publication number
MX2014013858A
MX2014013858A MX2014013858A MX2014013858A MX2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A MX 2014013858 A MX2014013858 A MX 2014013858A
Authority
MX
Mexico
Prior art keywords
treating
positive cancer
antibody
administering
patient
Prior art date
Application number
MX2014013858A
Other languages
English (en)
Inventor
Hans Loibner
Manfred Schuster
Evelyne Janzek-Hawlat
Susanne Wiederkum
Bernhard Peball
Stefan Stranner
Oliver Mutschlechner
Franz Groiss
Ruth Ladenstein
Holger Lode
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of MX2014013858A publication Critical patent/MX2014013858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un método para tratar un cáncer positivo de GD2 al administrar una preparación que comprende un anticuerpo anti-GD2 a un paciente como una infusión intravenosa continua durante 24 horas por día.
MX2014013858A 2012-06-18 2012-07-31 Metodo para tratar un cancer positivo de gd2. MX2014013858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2012/061618 WO2013189516A1 (en) 2012-06-18 2012-06-18 Method for treating a gd2 positive cancer
PCT/EP2012/064970 WO2013189554A1 (en) 2012-06-18 2012-07-31 Method for treating a gd2 positive cancer

Publications (1)

Publication Number Publication Date
MX2014013858A true MX2014013858A (es) 2015-02-12

Family

ID=46317406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013858A MX2014013858A (es) 2012-06-18 2012-07-31 Metodo para tratar un cancer positivo de gd2.

Country Status (15)

Country Link
US (4) US10294305B2 (es)
JP (1) JP6283665B2 (es)
KR (1) KR101927118B1 (es)
CN (1) CN104487088A (es)
AP (1) AP2014008129A0 (es)
AU (1) AU2012383254B2 (es)
BR (1) BR112014031806A8 (es)
CA (1) CA2876529C (es)
EA (1) EA038188B1 (es)
HK (1) HK1203375A1 (es)
IL (1) IL235696A0 (es)
MX (1) MX2014013858A (es)
SG (2) SG11201408487WA (es)
WO (2) WO2013189516A1 (es)
ZA (1) ZA201407961B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861251A1 (en) 2012-06-18 2015-04-22 Apeiron Biologics AG Method for treating a gd2 positive cancer
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
WO2015075194A1 (en) 2013-11-21 2015-05-28 Apeiron Biologics Ag Preparations and methods for treating a gd2 positive cancer
KR102614642B1 (ko) * 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
US10329323B2 (en) 2014-07-25 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Method for purifying antibodies using PBS
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
MX2020003201A (es) * 2017-09-21 2020-08-13 Umc Utrecht Holding Bv Anticuerpo anti-gd2 para el tratamiento del neuroblastoma.
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
WO2020165402A1 (en) 2019-02-14 2020-08-20 Westfälische Wilhelms-Universität Münster Gd2-upregulation by ezh2 inhibition in cancer therapy
WO2020236562A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2021020564A1 (ja) * 2019-08-01 2021-02-04 国立大学法人三重大学 Ｇｄ２結合性分子
EP4107187A1 (en) 2020-02-21 2022-12-28 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
KR20230066320A (ko) 2020-07-06 2023-05-15 유사 파마 (유케이) 리미티드 Gd2 양성 암을 치료하는 방법
EP4330289A1 (en) * 2021-07-05 2024-03-06 Trion Research GmbH Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4194471A1 (en) * 2021-12-10 2023-06-14 Y-Mabs Therapeutics, Inc. Anti-gd2 administration regimen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
EP2325205A3 (en) * 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
EP1941043B1 (en) 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
EP1916257A1 (en) 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
US8278065B2 (en) 2008-06-30 2012-10-02 Morphotek, Inc. Polynucleotides encoding anti-GD2 antibodies
CA2801210C (en) * 2010-06-19 2020-07-21 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
US8435972B2 (en) * 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
PT2771364T (pt) 2011-10-27 2019-09-10 Genmab As Produção de proteínas heterodiméricas
EP2861251A1 (en) 2012-06-18 2015-04-22 Apeiron Biologics AG Method for treating a gd2 positive cancer
WO2013189516A1 (en) 2012-06-18 2013-12-27 Apeiron Biologics Ag Method for treating a gd2 positive cancer
US9840566B2 (en) * 2013-11-21 2017-12-12 Apeiron Biologics Ag Preparations and methods for treating a GD2 positive cancer
WO2015075194A1 (en) 2013-11-21 2015-05-28 Apeiron Biologics Ag Preparations and methods for treating a gd2 positive cancer

Also Published As

Publication number Publication date
AU2012383254B2 (en) 2017-12-14
SG11201408487WA (en) 2015-02-27
WO2013189554A1 (en) 2013-12-27
CA2876529C (en) 2023-09-26
SG10201610532QA (en) 2017-02-27
CN104487088A (zh) 2015-04-01
EA201500019A1 (ru) 2015-05-29
US20200055953A1 (en) 2020-02-20
KR101927118B1 (ko) 2019-03-12
US20230340148A1 (en) 2023-10-26
US20140170155A1 (en) 2014-06-19
US11447565B2 (en) 2022-09-20
AU2012383254A1 (en) 2014-11-20
WO2013189516A1 (en) 2013-12-27
US10294305B2 (en) 2019-05-21
JP6283665B2 (ja) 2018-02-21
AP2014008129A0 (en) 2014-12-31
BR112014031806A8 (pt) 2018-01-16
ZA201407961B (en) 2015-10-28
KR20150030650A (ko) 2015-03-20
CA2876529A1 (en) 2013-12-27
JP2015521607A (ja) 2015-07-30
HK1203375A1 (en) 2015-10-30
EA038188B1 (ru) 2021-07-21
US20180134801A1 (en) 2018-05-17
IL235696A0 (en) 2015-01-29
BR112014031806A2 (pt) 2017-08-29

Similar Documents

Publication Publication Date Title
MX2014013858A (es) Metodo para tratar un cancer positivo de gd2.
MY170713A (en) Treatment protocol of diabetes type 2
MX340090B (es) Analogos de spliceostatina.
IN2014DN05986A (es)
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ608116A (en) Triazine-oxadiazoles
MX343706B (es) Derivados heterocíclicos novedosos.
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
MX2015004362A (es) Derivados de ketamina.
GEP201706690B (en) Novel process for making compounds for use in treatment of cancer
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
PH12014502065A1 (en) Vesicular formulations
NZ707773A (en) Methods of treating liver diseases
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
IN2014DN03010A (es)
NZ701974A (en) Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation
MX368640B (es) Composición farmacéutica para tratar inflamación y dolor.
WO2012112862A3 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
WO2013111013A8 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
MX2015016320A (es) Antibacteriano hibridos de oxazolidinona-quinolona para el tratamiento parenteral o profilaxis de enfermedades bacterianas.

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted